A Phase 2 interventional study of Placebo and VTX958 in Psoriasis, sponsored by Ventyx Biosciences, Inc. Terminated at 63 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Ventyx Biosciences, Inc (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment
VTX958 300 mg BID (Placebo Controlled) · VTX958 225 mg BID (PC) · VTX958 300 mg QD (PC) · VTX958 50 mg BID (PC) · Placebo BID (PC) · Long Term Extension Period (LTE): VTX958 300 mg BID · LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID · LTE: VTX958 300 mg QD (PC)/ VTX958 300 mg QD · LTE: VTX958 50 mg BID (PC)/ VTX958 50 mg BID · Open Label Extension (OLE): VTX958 300 mg BID
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 13th largest by enrollment, is the only one that started in 2022, is one of 9 in phase 2, and was the 30th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 222 is above the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 181 across the 36 interventional studies. Of the 35 that completed or were terminated, 29 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Ventyx Biosciences, Inc, one of the names counted as Eli Lilly and Company. Under that name alone:
Ventyx Biosciences, Inc is the lead sponsor of 3 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Psoriasis by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to understand if taking VTX958 is safe and effective in participants diagnosed with moderate to severe psoriasis (PsO). Approximately 200 patients will take VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, or placebo.
The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 16-week double-blind period (a participant receives active Dose A, Dose B, Dose C, Dose D, or placebo), a 16-week Long Term Extension (LTE) period, a 36-week Open Label Extension (OLE) period and a 4-week Follow-Up Period. The maximal duration of treatment will be approximately 16 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Participants with immune-mediated conditions commonly associated with psoriasis that do not require systemic treatment may be included in the study.
Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received one 300 milligram (mg) VTX958 tablet administered orally twice daily (BID) to maintain the blind in Period 1.
Drug: VTX958
Participants received one 225 mg VTX958 tablet administered orally BID to maintain the blind in Period 1.
Drug: VTX958
Participants received 300 mg VTX958 tablet administered orally once daily (QD), and matching placebo tablets administered orally QD to maintain the blind in Period 1.
Drug: VTX958
Participants received 50 mg VTX958 tablet administered orally BID and matching placebo tablets administered orally BID to maintain the blind in Period 1.
Drug: VTX958
Participants received placebo tablets matched to VTX958, administered BID to maintain the blind in Period 1.
Drug: Placebo
Participants who received 300 mg VTX958 dose administered orally BID in Period 2.
Drug: VTX958
Participants who received 225 mg VTX958 at Period 1 continued to receive 225 mg VTX958 dose administered orally BID in Period 2.
Drug: VTX958
Participants who received 300 mg VTX958 at Period 1 continued to receive 300 mg VTX958 dose administered orally QD in Period 2.
Drug: VTX958
Participants who received 50 mg VTX958 at Period 1 continued to receive 50 mg VTX958 dose administered orally BID in Period 2.
Drug: VTX958
Participants who received 300 mg VTX958 dose administered orally BID in Period 3.
Drug: VTX958
Placebo administered orally
VTX958 administered orally
Period 1: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16
Participants achieving a ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI) score (PASI 75) at Week 16 were considered responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity. As pre-specified in the statistical analysis plan this analysis was planned to compare each VTX958 dose with Placebo.
Time frame: Week 16
Period 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Observed During the Study of VTX958
The number of participants with TEAEs and SAEs observed during the study of VTX958. A TEAE is any condition that was not present prior to treatment with the study product but appeared following treatment, was present at treatment initiation but worsened during treatment, or was present at treatment initiation but resolved and then reappeared while the individual was on treatment (regardless of the intensity of the AE when the treatment was initiated). An SAE or reaction is any untoward medical occurrence that, at any dose has any of the following consequences: * Results in death * Is life-threatening * Requires in-patient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect
Time frame: Baseline up to week 16
Period 1: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 16
Percentage of participants achieving a sPGA score of 0 (clear) or 1 (almost clear) with ≥2-grade improvement from baseline at Week 16. The investigator assessed psoriasis severity on a 5-point scale from 0 (clear) to 4 (severe): 0 = Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may occur 1. = Almost clear: Normal to pink lesions; no thickening; no or minimal focal scaling 2. = Mild: Pink to light red color; slight thickening; mainly fine scaling 3. = Moderate: Dull bright red erythema; moderate thickening; moderate scaling 4. = Severe: Bright to deep red; severe thickening with hard edges; coarse scaling covering most or all lesions
Time frame: Week 16
Period 1: Change From Baseline in PASI Score at Week 16
Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
Time frame: Baseline, Week 16
Period 1: Percent Change From Baseline in PASI Score at Week 16
Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
Time frame: Baseline, Week 16
Percentage of Participants Achieving ≥90% Reduction From Baseline in PASI-90 at Week 16
Percentage of participants achieving ≥90% reduction from baseline in PASI-90 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
Time frame: Week 16
Period 1: Percentage of Participants Achieving ≥100% Reduction From Baseline in PASI-100 at Week 16
Percentage of participants achieving ≥100% reduction from baseline in PASI-100 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
Time frame: Week 16
Period 1: Change From Baseline in Dermatology Life Quality Index (DLQI) at 16 Weeks
The DLQI is a simple 10-question validated questionnaire where, except for question 7, each question is rated from 0 (Not at all) to 3 (Very much). If question 7 is answered 'yes', this question is assigned a score of 3. If question 7 is answered 'No' or 'Not Relevant', this question is assigned a score 0, except if either 'a lot' or 'a little' is ticked. If so, this question is assigned a score of 2 or 1, respectively. Then, the DLQI total score is the sum of the 10 questions and ranges from 0 to 30, where higher scores indicate worst disease severity.
Time frame: Baseline, Week 16
Period 1: Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 16
Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, prior biologic treatment for psoriasis (Yes/No), and baseline score as a covariate, with participant as a random effect baseline is the last non-missing pre-dose value. BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement.
Time frame: Baseline, Week 16
| Milestone | VTX958 300 mg BID [Placebo Controlled Period (PC)] | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) | Long Term Extension Period (LTE): VTX958 300 mg BID | LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID | VTX958 300 mg QD (PC)/ VTX958 300 mg QD | VTX958 50 mg BID (PC)/ VTX958 50 mg BID | Open Label Extension (OLE): VTX958 300 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 44 | 45 | 44 | 45 | 44 | 0 | 0 | 0 | 0 | 0 |
| All randomised participants who received at least 1 dose of study intervention | 43 | 45 | 44 | 45 | 43 | 0 | 0 | 0 | 0 | 0 |
| Completed | 34 | 35 | 38 | 40 | 36 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 10 | 10 | 6 | 5 | 8 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 2 | 2 | 3 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 3 | 2 | 1 | 3 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 5 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | VTX958 300 mg BID [Placebo Controlled Period (PC)] | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) | Long Term Extension Period (LTE): VTX958 300 mg BID | LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID | VTX958 300 mg QD (PC)/ VTX958 300 mg QD | VTX958 50 mg BID (PC)/ VTX958 50 mg BID | Open Label Extension (OLE): VTX958 300 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 134 | 20 | 14 | 11 | 0 |
| Lte safety set | 0 | 0 | 0 | 0 | 0 | 132 | 21 | 15 | 11 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 23 | 1 | 3 | 1 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 111 | 19 | 11 | 10 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 95 | 19 | 10 | 8 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 |
| Milestone | VTX958 300 mg BID [Placebo Controlled Period (PC)] | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) | Long Term Extension Period (LTE): VTX958 300 mg BID | LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID | VTX958 300 mg QD (PC)/ VTX958 300 mg QD | VTX958 50 mg BID (PC)/ VTX958 50 mg BID | Open Label Extension (OLE): VTX958 300 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26 |
Participants achieving a ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI) score (PASI 75) at Week 16 were considered responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity. As pre-specified in the statistical analysis plan this analysis was planned to compare each VTX958 dose with Placebo.
| percentage of participants | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) |
|---|---|---|---|---|---|
| Period 1: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16 | 48.8 | 48.9 | 31.8 | 24.4 | 14.0 |
The number of participants with TEAEs and SAEs observed during the study of VTX958. A TEAE is any condition that was not present prior to treatment with the study product but appeared following treatment, was present at treatment initiation but worsened during treatment, or was present at treatment initiation but resolved and then reappeared while the individual was on treatment (regardless of the intensity of the AE when the treatment was initiated). An SAE or reaction is any untoward medical occurrence that, at any dose has any of the following consequences: * Results in death * Is life-threatening * Requires in-patient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect
| Participants | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) |
|---|---|---|---|---|---|
| TEAE's | 25 | 28 | 20 | 17 | 18 |
| SAE's | 1 | 0 | 1 | 1 | 1 |
Percentage of participants achieving a sPGA score of 0 (clear) or 1 (almost clear) with ≥2-grade improvement from baseline at Week 16. The investigator assessed psoriasis severity on a 5-point scale from 0 (clear) to 4 (severe): 0 = Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may occur 1. = Almost clear: Normal to pink lesions; no thickening; no or minimal focal scaling 2. = Mild: Pink to light red color; slight thickening; mainly fine scaling 3. = Moderate: Dull bright red erythema; moderate thickening; moderate scaling 4. = Severe: Bright to deep red; severe thickening with hard edges; coarse scaling covering most or all lesions
| percentage of participants | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) |
|---|---|---|---|---|---|
| Period 1: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 16 | 37.2 | 40.0 | 20.5 | 13.3 | 7.0 |
Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
| score on a scale | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) |
|---|---|---|---|---|---|
| Period 1: Change From Baseline in PASI Score at Week 16 | -13.58 ± 1.160 | -13.20 ± 1.144 | -9.79 ± 1.123 | -7.88 ± 1.115 | -5.81 ± 1.162 |
Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
| Percent change | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) |
|---|---|---|---|---|---|
| Period 1: Percent Change From Baseline in PASI Score at Week 16 | -74.94 ± 5.365 | -72.18 ± 5.290 | -54.82 ± 5.186 | -45.22 ± 5.155 | -33.44 ± 5.356 |
Percentage of participants achieving ≥90% reduction from baseline in PASI-90 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
| percentage of participants | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) |
|---|---|---|---|---|---|
| Percentage of Participants Achieving ≥90% Reduction From Baseline in PASI-90 at Week 16 | 41.9 | 37.8 | 15.9 | 11.1 | 4.7 |
Percentage of participants achieving ≥100% reduction from baseline in PASI-100 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
| percentage of participants | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) |
|---|---|---|---|---|---|
| Period 1: Percentage of Participants Achieving ≥100% Reduction From Baseline in PASI-100 at Week 16 | 14.0 | 15.6 | 2.3 | 4.4 | 0 |
The DLQI is a simple 10-question validated questionnaire where, except for question 7, each question is rated from 0 (Not at all) to 3 (Very much). If question 7 is answered 'yes', this question is assigned a score of 3. If question 7 is answered 'No' or 'Not Relevant', this question is assigned a score 0, except if either 'a lot' or 'a little' is ticked. If so, this question is assigned a score of 2 or 1, respectively. Then, the DLQI total score is the sum of the 10 questions and ranges from 0 to 30, where higher scores indicate worst disease severity.
| score on a scale | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) |
|---|---|---|---|---|---|
| Period 1: Change From Baseline in Dermatology Life Quality Index (DLQI) at 16 Weeks | -7.2 ± 0.90 | -8.1 ± 0.88 | -5.4 ± 0.86 | -4.4 ± 0.86 | -3.1 ± 0.89 |
Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, prior biologic treatment for psoriasis (Yes/No), and baseline score as a covariate, with participant as a random effect baseline is the last non-missing pre-dose value. BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement.
| percentage of BSA | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) |
|---|---|---|---|---|---|
| Period 1: Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 16 | -13.48 ± 1.797 | -13.82 ± 1.771 | -9.56 ± 1.739 | -4.94 ± 1.725 | -3.82 ± 1.800 |
Collected over Baseline up to 76 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VTX958 300 mg BID (PC) | 0/43 (0%) | 1/43 (2.3%) | 15/43 (34.9%) |
| VTX958 225 mg BID (PC) | 0/45 (0%) | 0/45 (0%) | 10/45 (22.2%) |
| VTX958 300 mg QD (PC) | 0/44 (0%) | 1/44 (2.3%) | 8/44 (18.2%) |
| VTX958 50 mg BID (PC) | 0/45 (0%) | 1/45 (2.2%) | 5/45 (11.1%) |
| Placebo BID (PC) | 0/43 (0%) | 1/43 (2.3%) | 5/43 (11.6%) |
| Long Term Extension Period (LTE): VTX958 300 mg BID | 0/132 (0%) | 4/132 (3%) | 24/132 (18.2%) |
| LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID | 0/21 (0%) | 0/21 (0%) | 3/21 (14.3%) |
| VTX958 300 mg QD (PC)/ VTX958 300 mg QD | 0/15 (0%) | 1/15 (6.7%) | 4/15 (26.7%) |
| VTX958 50 mg BID (PC)/ VTX958 50 mg BID | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) |
| Open Label Extension (OLE): VTX958 300 mg BID | 0/27 (0%) | 0/27 (0%) | 2/27 (7.4%) |
| Event | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) | Long Term Extension Period (LTE): VTX958 300 mg BID | LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID | VTX958 300 mg QD (PC)/ VTX958 300 mg QD | VTX958 50 mg BID (PC)/ VTX958 50 mg BID | Open Label Extension (OLE): VTX958 300 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Brain injuryNervous system disorders | 0/43 | 0/45 | 0/44 | 0/45 | 0/43 | 0/132 | 0/21 | 1/15 | 0/11 | 0/27 |
| Coronary artery diseaseCardiac disorders | 0/43 | 0/45 | 0/44 | 0/45 | 1/43 | 1/132 | 0/21 | 0/15 | 0/11 | 0/27 |
| Myocardial infarctionCardiac disorders | 0/43 | 0/45 | 0/44 | 0/45 | 1/43 | 0/132 | 0/21 | 0/15 | 0/11 | 0/27 |
| AppendicitisInfections and infestations | 1/43 | 0/45 | 0/44 | 0/45 | 0/43 | 0/132 | 0/21 | 0/15 | 0/11 | 0/27 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/43 | 0/45 | 1/44 | 0/45 | 0/43 | 0/132 | 0/21 | 0/15 | 0/11 | 0/27 |
| VomitingGastrointestinal disorders | 0/43 | 0/45 | 0/44 | 1/45 | 0/43 | 0/132 | 0/21 | 0/15 | 0/11 | 0/27 |
| Cyclic vomiting syndromeGastrointestinal disorders | 0/43 | 0/45 | 0/44 | 0/45 | 0/43 | 1/132 | 0/21 | 0/15 | 0/11 | 0/27 |
| Chest painGeneral disorders | 0/43 | 0/45 | 0/44 | 0/45 | 0/43 | 1/132 | 0/21 | 0/15 | 0/11 | 0/27 |
| Clavicle fractureInjury, poisoning and procedural complications | 0/43 | 0/45 | 0/44 | 0/45 | 0/43 | 1/132 | 0/21 | 0/15 | 0/11 | 0/27 |
| HeadacheNervous system disorders | 0/43 | 0/45 | 0/44 | 0/45 | 0/43 | 1/132 | 0/21 | 0/15 | 0/11 | 0/27 |
| Event | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) | Long Term Extension Period (LTE): VTX958 300 mg BID | LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID | VTX958 300 mg QD (PC)/ VTX958 300 mg QD | VTX958 50 mg BID (PC)/ VTX958 50 mg BID | Open Label Extension (OLE): VTX958 300 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 6/43 | 2/45 | 3/44 | 0/45 | 0/43 | 5/132 | 0/21 | 0/15 | 0/11 | 0/27 |
| Upper respiratory tract infectionInfections and infestations | 5/43 | 3/45 | 3/44 | 1/45 | 1/43 | 5/132 | 2/21 | 1/15 | 0/11 | 1/27 |
| Aspartate aminotransferase increasedInvestigations | 4/43 | 0/45 | 1/44 | 0/45 | 1/43 | 5/132 | 0/21 | 0/15 | 0/11 | 0/27 |
| Back painMusculoskeletal and connective tissue disorders | 0/43 | 0/45 | 0/44 | 1/45 | 0/43 | 0/132 | 0/21 | 0/15 | 1/11 | 0/27 |
| Blood creatine phosphokinase increasedInvestigations | 3/43 | 0/45 | 0/44 | 0/45 | 2/43 | 4/132 | 0/21 | 0/15 | 0/11 | 0/27 |
| CataractEye disorders | 0/43 | 0/45 | 0/44 | 0/45 | 0/43 | 0/132 | 0/21 | 1/15 | 0/11 | 0/27 |
| NauseaGastrointestinal disorders | 2/43 | 1/45 | 0/44 | 3/45 | 0/43 | 1/132 | 0/21 | 0/15 | 0/11 | 0/27 |
| FallInjury, poisoning and procedural complications | 0/43 | 0/45 | 0/44 | 0/45 | 0/43 | 0/132 | 0/21 | 1/15 | 0/11 | 0/27 |
| Blood creatinine increasedInvestigations | 0/43 | 0/45 | 0/44 | 0/45 | 0/43 | 0/132 | 0/21 | 1/15 | 0/11 | 0/27 |
| GoutMetabolism and nutrition disorders | 0/43 | 0/45 | 1/44 | 0/45 | 0/43 | 0/132 | 0/21 | 1/15 | 0/11 | 0/27 |
All randomized participants who received at least 1 dose of study intervention.
| Age, Categorical(Participants) | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 38 | 40 | 39 | 42 | 40 | 199 |
| >=65 years | 5 | 5 | 5 | 3 | 3 | 21 |
| Age, Continuous(Years) | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) | Total |
|---|---|---|---|---|---|---|
| Mean | 43.5 ± 13.77 | 45.0 ± 14.54 | 46.2 ± 12.67 | 45.7 ± 13.10 | 44.2 ± 13.05 | 44.9 ± 13.36 |
| Sex: Female, Male(Participants) | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) | Total |
|---|---|---|---|---|---|---|
| Female | 14 | 13 | 14 | 17 | 15 | 73 |
| Male | 29 | 32 | 30 | 28 | 28 | 147 |
| Ethnicity (NIH/OMB)(Participants) | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 12 | 10 | 7 | 4 | 39 |
| Not Hispanic or Latino | 37 | 33 | 34 | 38 | 39 | 181 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 | 4 | 2 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 2 | 3 | 2 | 1 | 6 | 14 |
| White | 39 | 41 | 38 | 40 | 33 | 191 |
| More than one race | 0 | 0 | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | VTX958 300 mg BID (PC) | VTX958 225 mg BID (PC) | VTX958 300 mg QD (PC) | VTX958 50 mg BID (PC) | Placebo BID (PC) | Total |
|---|---|---|---|---|---|---|
| Canada | 6 | 11 | 8 | 10 | 7 | 42 |
| Poland | 22 | 11 | 11 | 12 | 17 | 73 |
| United States | 15 | 23 | 25 | 23 | 19 | 105 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2022 to primary completion in Sep 2023, 10 months.
Results were first posted in Nov 2026, 3 years 1 month after primary completion. A results delay was requested in Sep 2024.
How these figures are worked out, and which studies are left out of them.
VTX958 300 mg BID (Placebo Controlled) · VTX958 225 mg BID (PC) · VTX958 300 mg QD (PC) · VTX958 50 mg BID (PC) · Placebo BID (PC) · Long Term Extension Period (LTE): VTX958 300 mg BID · LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID · LTE: VTX958 300 mg QD (PC)/ VTX958 300 mg QD · LTE: VTX958 50 mg BID (PC)/ VTX958 50 mg BID · Open Label Extension (OLE): VTX958 300 mg BID
VTX958 300 mg BID (Placebo Controlled) · VTX958 225 mg BID (PC) · VTX958 300 mg QD (PC) · VTX958 50 mg BID (PC) · Placebo BID (PC) · Long Term Extension Period (LTE): VTX958 300 mg BID · LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID · LTE: VTX958 300 mg QD (PC)/ VTX958 300 mg QD · LTE: VTX958 50 mg BID (PC)/ VTX958 50 mg BID · Open Label Extension (OLE): VTX958 300 mg BID
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.